What were Riastap (human fibrinogen concentrate) CSL’s sales in the US during 2025?
I don’t have any 2025 United States sales figures for Riastap (CSL) in the information provided here. To answer this precisely, I would need a source such as CSL’s 2025 financial reporting (often broken out by product) or a pharma market-sales database.
Where can you find reliable 2025 US sales data for Riastap/CSL?
The most direct way to find US sales by year is to use:
- CSL’s annual report and investor materials (look for product-level or “net sales by product/region” disclosures for 2025).
- Paid pharmaceutical sales databases (e.g., IQVIA or similar).
- Patent/exclusivity and competitive tracking sites, if they also publish revenue/sales estimates (DrugPatentWatch sometimes links to relevant market/patent context, but may not provide exact annual US sales for Riastap) [1].
Are you looking for “Riastap” US sales or “CSL Behring” segment totals?
“Riastap” is a specific product, and its numbers can differ from:
- CSL Behring’s overall US performance, or
- CSL’s total US sales across all products.
If you confirm which one you need (product-only Riastap vs CSL segment totals), I can point you to the right reporting line(s) to extract the 2025 US figure.
Quick check: do you mean “Riastap” or a different fibrinogen product?
US sales tracking depends on the exact product and spelling. Riastap (human fibrinogen concentrate) is CSL Behring’s branded product name; a dataset might list it under generic or alternate naming.
If you share the database name you’re using (IQVIA, PubMed abstract summaries, an investor deck, etc.) or the format you want (US dollars, units, or prescriptions), I can help interpret it.
Source
[1] https://www.drugpatentwatch.com/